The effective rate of Johnson & Johnson HIV vaccine phase II trial in Africa is only 25%
It is reported that Johnson & Johnson HVTN 705 / hpx2008 vaccine has recruited nearly 2600 young women in five countries in sub Saharan Africa. In 2020, young women in this region accounted for 63% of the new HIV infections in the world. The vaccine needs to be vaccinated four times in total, and the time of test data analysis is two years after the first vaccination. According to statistics, 63 of 1109 people vaccinated with placebo were infected with the virus, while 51 of 1079 people vaccinated were infected with the virus, with a corresponding effective rate of 25.2%. Johnson & Johnson said that the overall tolerance of the vaccine was good, and there were no serious adverse reactions during the trial.
It is worth mentioning that Johnson & Johnson’s vaccine uses the same adenovirus platform as the company’s new crown vaccine, and has been supported by the National Institute of national and infectious diseases (NIAID) and the gates Melinda foundation. Dr. fudge, director of NIAID, commented that although the results of this experiment are certainly not what we expected, we must make full use of the experience gained from this experiment.
Paul Stoffels, vice chairman of Johnson & Johnson Executive Committee and chief scientific officer, said that HIV is a unique and complex virus, which has long posed unprecedented challenges to vaccine development because it has the ability to attack, hijack and escape the human immune system. Although we are disappointed that the candidate vaccine does not provide sufficient protection, this study also provides us with important scientific findings to help us continue to find vaccines that can prevent HIV.
In addition to the vaccine tested in Africa, Johnson & Johnson is also conducting phase III test of another HIV vaccine HVTN 706 / hpx3002 in Europe and America, which is mainly aimed at another group of susceptible people. At the same time, the HIV strains prevalent in Europe and America are also different from those in Africa.
Although there are effective treatments to alleviate the virus in the medical community, HIV vaccine is still a crucial link from the perspective of virus. At present, trials of mixing different vaccines are still under way in Africa, and the highly anticipated Moderna HIV vaccine will also be put into human trials within this year.